Exhibit 99.3

Sinovac Reports Unaudited Second Quarter 2013 Financial Results

- Conference call scheduled for Wednesday, August 14, 2013 at 8:00 AM EDT

BEIJING, Aug. 13, 2013 /PRNewswire/ -- Sinovac Biotech Ltd. (SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited second quarter and half year financial results for the period ended June 30, 2013.

Second Quarter 2013 Financial Highlights (period-over-period comparisons to second quarter 2012)

· Total sales increased by 86.4% to $17.5 million from $9.4 million.

· Gross profit increased by 70.1% to $13.6 million from $8.0 million.

· Net income attributable to common stockholders was $1.3 million, or $0.02 per basic and diluted share, compared to net loss attributed to common stockholders of $1.6 million, or $0.03 per basic and diluted share.

· Cash and cash equivalents totaled $92.0 million as of June 30, 2013, compared to $91.2 million as of December 31, 2012.

Recent Business Highlights

On July 30, 2013, following the completion of inspection on clinical sites by the Beijing Drug Administration, Sinovac's registration documentations for its proprietary EV71 vaccine were submitted to and accepted by the Center for Drug Evaluation (CDE), China Food and Drug Administration for the technological review on Sinovac's new drug application (NDA) filing.

On August 6, 2013, the phase II clinical results for Sinovac's proprietary EV71 vaccine were published online in The Journal of Infectious Diseases (JID), the premier global journal for original research on infectious diseases. The paper is entitled "Immunogenicity, Safety, and Immune Persistence of A Novel Inactivated Human Enterovirus 71 (EV71) Vaccine: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial."

Dr. Weidong Yin, Chairman, President and CEO, commented, "We are pleased to report another quarter with strong sales rising by 86.4%, driven by robust hepatitis vaccines sales resulting from a favorable competitive environment in China and successful initiatives focused on each market segment implemented by our sales team.  With this diversified sales strategy, Sinovac is poised to maximize the upcoming commercial opportunity for our EV71 vaccine for which the NDA filing is under review in China. The top line growth in the current period was the key driver of a higher gross profit and a higher net income as compared to previous quarters."

Dr. Yin continued, "The review of our NDA filing for our EV71 vaccine is also moving forward to the technological review process by the CDE. Hand, foot and mouth disease (HFMD) continues to represent a significant unmet medical need in China with reports of over 900,000 HFMD cases and 156 fatalities in first half of 2013. We aim to launch the EV71 vaccine to provide a solution to address this unmet medical need as no treatment and prevention options exist for this highly contagious disease impacting children in China and surrounding countries."

Financial Review for Second Quarter Ended June 30, 2013

An analysis of sales and gross profit is as follows:

In USD'000	2013Q2		% of total sales			2012Q2		% of total sales
	(Unaudited)		(Unaudited)			(Unaudited)		(Unaudited)
Hepatitis A(Healive)		7,021		40.2	%		3,561		38.0	%
Hepatitis A&B(Bilive)		9,586		54.9	%		6,070		64.8	%
Hepatitis vaccines		16,607		95.1	%		9,631		102.8	%
Influenza vaccines		48		0.3	%		-268		-2.9	%
Core sales		16,655		95.4	%		9,363		99.9
Animal vaccine		64		0.4	%		2		0.01	%
Mumps		732		4.2	%		-		-
Total sales		17,451		100	%		9,365		100	%
Cost of goods sold		3,861					1,376
Gross profit		13,590		77.9	%		7,989		85.3	%

Total sales increased by 86.4% to $17.5 million in the second quarter of 2013 from $9.4 million in the second quarter of 2012. Both Healive and Bilive contributed to the sales growth in the second quarter, resulting from the favorable competitive environment in the private pay market in China and initiatives implemented by the Company's sales team.

Gross profit increased by 70.1% to $13.6 million for the second quarter of 2013 from $8.0 million in the same period of 2012. Gross margin was 77.9% in the second quarter of 2013, compared to 85.3% in the same period of 2012. Excluding the impact of the H5N1 inventory provision of $0.2 million, the gross margin was 79.0% in the second quarter of 2013. The decline in gross margin was affected by the sales of different products mix with different gross margin.

SG&A expenses for the second quarter of 2013 were $8.3 million, compared to $6.7 million in the same period of 2012. Selling expenses as a percentage of second quarter 2013 sales was 32.0%, compared to 38.9% during the second quarter of the prior year. The decrease in selling expense as a percentage of revenue was mainly due to the increased sales team productivity.

The G&A expenses for the second quarter of 2013 decreased to $2.7 million from $3.1 million in the second quarter of 2012. The decrease was mainly due to the effect that the bonuses, paid out or to be paid out, were recorded against a previously accrued liability account, named staff benefits, rather than charged to expenses. This had the effect of partially offsetting increased G&A resulting from the higher operating costs because the Company's Changping site is now fully operational. A part of the operating cost increase was related to the ongoing validation activities on the manufacturing facilities in support of the EV71 vaccine for which the NDA is currently under review.

R&D expenses in the second quarter of 2013 were $2.0 million, a decrease from $4.7 million in the same period of 2012. The lower R&D expenses in the current quarter were attributable to the completion of the phase III study of EV71 vaccine candidate in the first quarter of 2013. The R&D activities in the second quarter focused on the other vaccine candidates in the Company's pipeline.

Depreciation of property, plant and equipment and amortization of licenses and permits for the second quarter of 2013 were $0.5 million, compared to $0.3 million for the same period of last year. Depreciation increased because more assets were in service at the Changping facility as compared to the second quarter of 2012.

Net income attributable to common stockholders was $1.3 million, or $0.02 per basic share and diluted share, for the second quarter of 2013, compared to a net loss attributed to common stockholders of $1.6 million, or $0.03 per basic and diluted share, for the second quarter of 2012. Excluding the impact of the bonus revision of $1.6 million, which was paid out or to be paid out from an accrued liability account rather than charged to expenses, the net loss of the second quarter of 2013 would approximately be $0.3 million, or $0.01 per basic share and diluted share.

Financial Review for the Six Months Period Ended June 30, 2013

An analysis of sales and gross profit is as follows:

In USD'000	2013 YTD		% of total sales			2012 YTD		% of total sales
	(Unaudited)		(Unaudited)			(Unaudited)		(Unaudited)
Hepatitis A(Healive)		13,199		48.0	%		5,172		33.7	%
Hepatitis A&B(Bilive)		12,581		45.7	%		10,085		65.8	%
Hepatitis vaccines		25,780		93.7	%		15,257		99.5	%
Influenza vaccines		330		1.2	%		46		0.3	%
Core sales		26,110		94.9	%		15,303		99.8	%
Animal vaccine		78		0.3	%		35		0.2	%
Mumps		1,316		4.8	%		-		-
Total sales		27,504		100	%		15,338		100	%
Cost of goods sold		6,853					3,631
Gross profit		20,651		75.1	%		11,707		76.3	%

Total sales were increased by 79.3% to $27.5 million in first half of 2013 from $15.3 million in the same period of 2012. The sales growth was achieved across every sales channel, including the public market, private market and sales through distributors, which demonstrated the success of the Company's sales strategy of combining a diversified sales model to largely improve the market coverage and penetration.

Gross profit of the first half year of 2013 increased by 76.4% to $20.7 million from $11.7 million in the same period of 2012. Gross margin was 75.1%, compared to 76.3% of the same period of last year. Excluding the impact of the H5N1 inventory provision of $0.8 million, the gross margin was 78.1%.

Selling, general and administrative expenses for the first half of 2013 were $14.6 million, compared to $11.0 million in the same period of 2012. Selling expenses as a percentage of first half year of 2013 sales was 31.3%, compared to 37.9% of first half year of the prior year. The G&A expenses increased to $6.0 million in the first half of 2012 from $5.2 million for the first half year of the prior year. The factors affecting selling, general and administrative expenses for the first half of 2013 were the same as for the second quarter, described above.

Research and development expenses for the first half of 2013 was $3.9 million, a $8.1 million decrease from $12.0 million for the same period in 2012.  The lower R&D expenses were attributable to the completion of the phase III trial for the EV71 vaccine.

Depreciation of property, plant and equipment and amortization of licenses and permits for first half year of 2013 was $1.3 million, compared to $0.6 million for the same period of last year. Depreciation increased because more assets were in service at the Changping facility compared to the same period in 2012.

Net loss attributable to stockholders in the first half of 2013 was $0.7 million, or $0.01 per basic and diluted share, compared to a net loss of $7.2 million, or $0.13 per basic and diluted share, for the same period of last year. Excluding the impact of the bonus revision of $1.6 million, which was paid out from an accrued liability account rather than charged to expenses, the net loss of the first half year of 2013 would approximately be $2.3 million, or $0.04 per basic share and diluted share.

As of June 30, 2013, cash and cash equivalents totaled $92.0 million, compared to $91.2 million as of December 31, 2012. Net cash used in operating activities was $9.3 million in the first half of 2013. Net cash used in investing activities was $2.2 million, which was mainly used to acquire property, plant and equipment for the Changping site. Net cash provided by financing activities was $11.6 million in the first half of 2013, including loan proceeds of $10.8 million.  The Company continues to source new financing resources to commercialize other pipeline products when appropriate.

Management Change

Ms. Nan Wang, Vice President of Sinovac, has been appointed as Chief Financial Officer, effective June 1, 2013. Mr. Danny Chung, who was Chief Financial Officer, has resigned for family reasons.

Other Developments

Sinovac owns a controlling 73.09% interest in Sinovac Biotech Co., Ltd. (Sinovac Beijing), while Sino Bioway holds the remaining 26.91% non-controlling interest. On April 8, 2013, the board of directors of Sinovac Beijing approved the transfer of Sino Bioway's interest in Sinovac Beijing to a subsidiary of Sino Bioway, Xiamen Bioway Biotech Co., Ltd. The transfer was completed on May 13, 2013. There was no impact on Sinovac Beijing's daily operations and no change to the composition of the board of directors of Sinovac Beijing after the completion of the transaction.

Conference Call Details

The Company will host a conference call prior to the market opening on Wednesday, August 14, 2013, at 8:00 a.m. EDT (August 14, 2013 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent corporate developments. To access the conference call, please dial 1-877-407-0784 (USA) or 1-201-689-8560 (International).  A replay of the call will be available from 11 a.m. EDT on August 14, 2013, to August 28, 2013, at midnight. To access the replay, please dial 1-877-870-5176 (USA) or 1-858-384-5517 (International) and reference the replay pin number 418775.

A live audio webcast of the call will also be available from the investors section on the corporate web site at www.sinovac.com.  A webcast replay can be accessed on the corporate website beginning August 14, 2013, and the replay will remain available for 30 days.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases including hepatitis A and B, seasonal influenza, H5N1 pandemic influenza (avian flu), H1N1 influenza (swine flu) and mumps, as well as animal rabies vaccine for canines. The Company recently concluded the phase III clinical trial for enterovirus 71 (against hand, foot and mouth disease) and filed new drug application with China Food & Drug Administration.  In 2009, Sinovac was the first company worldwide to receive approval for its H1N1 influenza vaccine, Panflu.1, and has manufactured it for the Chinese Central Government, pursuant to the government-stockpiling program.  The Company is also the only supplier of the H5N1 pandemic influenza vaccine to the government-stockpiling program. Sinovac is developing a number of new pipeline vaccines including vaccines for pneumococcal polysaccharides, pneumococcal conjugate, varicella and rubella. Sinovac sells its vaccines mainly in China and exports selected vaccines to Mongolia, Nepal, and the Philippines. Sinovac has also been granted a license to commercialize seasonal flu vaccine in Mexico.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar statements. Among other things, the business outlook and quotations from management in this press release contain forward-looking statements. Statements that are not historical facts, including statements about Sinovac's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. Sinovac does not undertake any obligation to update any forward-looking statement, except as required under applicable law.

Helen Yang/Chris Lee
Sinovac Biotech Ltd.
Tel:  +86-10-8279-9659/9696
Fax:  +86-10-6296-6910
Email: ir@sinovac.com

Investors:
Stephanie Carrington
The Ruth Group
Tel:  +1-646-536-7017
Email: scarrington@theruthgroup.com

Media:
Aaron Estrada
The Ruth Group
Tel:  +1-646-536-7028
Email: aestrada@theruthgroup.com

SINOVAC BIOTECH LTD.

Consolidated Balance Sheets

(Unaudited)

June 30,2013

(Expressed in U.S. Dollars)

	June 30, 2013			December 31, 2012
Cash and cash equivalents		92,046,428			91,240,956
Accounts receivable		31,248,974			23,440,135
Inventories		16,655,331			10,529,476
Prepaid expenses and deposits		914,771			1,072,078
Total current assets		140,865,504			126,282,645
Property, plant and equipment		79,838,322			80,083,383
Long-term inventory		-			28,692
Long-term prepaid expenses		213,310			289,766
Deposits for acquisition of equipment		280,534			483,278
Deferred tax asset		467,490			445,589
License and permit		964,416			1,149,914
Total assets		222,629,576			208,763,267
Current liabilities
Loans payable		6,213,808			3,328,590
Accounts payable and accrued liabilities		26,522,072			24,777,808
Income tax payable		242,381			238,775
Deferred revenue		59,471			1,378,425
Deferred research grants		437,609			431,097
Total current liabilities		33,475,341			30,154,695
Deferred research grants		4,593,360			4,068,602
Loans payable		39,425,475			31,181,235
Due to related party		3,278,261			3,230,125
Deferred revenue		10,955,779			10,693,247
Total long-term liabilities		58,252,875			49,173,209
Total liabilities		91,728,216			79,327,904
Commitments and contingencies
Stockholder's equity
Common stock		55,353			55,092
Additional paid in capital		106,808,942			106,245,934
Accumulated other comprehensive income		12,983,039			11,770,927
Dedicated reserves		11,808,271			11,808,271
Accumulated deficit		(12,845,353	)		(12,156,414	)
Total stockholders' equity		118,810,252			117,723,810
Non-controlling interest		12,091,108			11,711,553
Total equity		130,901,360			129,435,363
Total equity and liability		222,629,576			208,763,267

SINOVAC BIOTECH LTD.

Consolidated Statements of Operations and Comprehensive Income (loss)

June 30,2013

(Unaudited)

(Expressed in U.S. Dollars)

	Three Months ended June 30						Six Months ended June 30
	2013			2012			2013			2012
Sales		17,451,442			9,364,632			27,503,657			15,338,099
Cost of sales (exclusive of depreciation of land use right and amortization of licenses and permits of $201,211(2012-$67,486) for three months and $97,449(2012-$12,507) for six months		3,860,856			1,375,917			6,852,720			3,631,206
Gross profit		13,590,586			7,988,715			20,650,937			11,706,893
Selling, general and administrative expenses		8,265,312			6,700,526			14,628,669			11,020,815
Provision for doubtful account		603,601						885,791			-
Research and development expenses		2,041,639			4,676,703			3,889,246			12,018,875
Depreciation of property, plant and equipment and amortization of licenses		541,720			313,265			1,313,866			620,708
Loss (gain) on disposal and impairment of property, plant and equipment		82			-			(2,319	)		-
Government grants recognized in income		-			(405,082	)					(476,286	)
Total operating expenses		11,452,354			11,285,412			20,715,253			23,184,112
Operating income (loss)		2,138,232			(3,296,697	)		(64,316	)		(11,477,219	)
Interest and financing expenses		(770,319	)		(232,078	)		(1,433,406	)		(446,398	)
Interest income		582,602			498,856			1,023,920			1,096,527
Other income (expenses)		(53,667	)		14,635			7,095			132,713
Income (loss) before income taxes and Minority interest		1,896,848			(3,015,284	)		(466,707	)		(10,694,377	)
Income tax recovery		17,272			797,462			14,783			800,364
Consolidated net income (loss)		1,914,120			(2,217,822	)		(451,924	)		(9,894,013	)
Net Income (loss) attributable to the noncontrolling interest		595,222			(587,684	)		237,015			(2,650,820	)
Net income (loss) attributable to stockholders		1,318,898			(1,630,138	)		(688,939	)		(7,243,193	)
Net income (loss)		1,914,120			(2,217,822	)		(451,924	)		(9,894,013	)
Foreign currency translation adjustment		1,118,992			(469,734	)		1,352,701			177,049
Total comprehensive income (loss)		3,033,112			(2,687,556	)		900,777			(9,716,964	)
Less: comprehensive (income) loss attributable to non-controlling interests		706,887			(633,486	)		377,604			(2,613,075	)
Comprehensive income (loss) attributable to stockholders		2,326,225			(2,054,070	)		523,173			(7,103,889	)
Weighted average number of shares of
Basic		55,056,191			54,804,498			54,995,674			54,784,801
Diluted		55,522,748			54,804,498			54,995,674			54,784,801
Basic and diluted earnings (loss) per share		0.02			(0.03	)		(0.01	)		(0.13	)

SINOVAC BIOTECH LTD.

Consolidated Statements of Cash Flow

June 30,2013

(Unaudited)

(Expressed in U.S. Dollars)

	Three Months ended June 30						Six Months ended June 30
	2013			2012			2013			2012
Cash flows used in operating activities:
Net income (loss) for the period		1,914,120			(2,217,822	)		(451,924	)		(9,894,013	)
deferred income tax		(17,272	)		69,231			(14,783	)		66,329
stock-based compensation		61,854			173,791			137,693			253,966
inventory provison		767,811			1,239,399			767,811			1,325,263
provision for (recovery of) doubtful allowance		603,602			-			885,792			-
Impairment of equipment and losses(gain) on disposal		82			2,460			(2,319	)		2,460
unrealized foreign exchange gain (loss)		-			166,701			-			(43,880	)
research and development expenditures qualified for  government grant		-			-			-			(79,116	)
depreciation of property, plant and equipment,		1,787,173			1,293,974			3,485,540			2,546,524
deferred government grants recognized as income		-			(325,965	)					(397,169	)
accreation expenses		34,282			68,398			52,373			136,789
Changes in assets and liabilities:
accounts receivable, trade		(4,510,518	)		614,574			(8,287,685	)		(671,232	)
inventory		(3,581,987	)		(4,845,918	)		(6,657,043	)		(6,165,393	)
income tax payable		-			(3,136,687	)		-			(3,124,477	)
prepaid expenses and deposits		399,292			(293,778	)		255,543			488,378
defer revenue		(161,644	)		(5	)		(1,228,643	)		(99,522	)
accounts payables and accrued liabilities		(592,990	)		882,535			1,753,684			(2,522,272	)
Net cash used by operating activities		(3,296,195	)		(6,309,112	)		(9,303,961	)		(18,177,365	)
Cash flows from financing activities
Loan proceed		3,304,721			3,985,568			10,784,502			6,009,507
Loan Payments		(161,606	)		-			(161,606	)		-
Proceeds from issuance of common stock		406,240			343,040			417,120			393,440
Subscription received		8,456			2,400			8,456			2,400
Dividends paid to non-controlling shareholder of Sinovac Beijing		-			-			-			(800,717	)
Loan from non-controlling shareholder of Sinovac Dalian		-			-			-			3,175,266
Government grant received		220,187			240,580			523,813			240,580
Net cash provided by financing activities		3,777,998			4,571,588			11,572,285			9,020,476
Cash flows used in investing activities:
Prepayments for acquisition of equipment		346,884			1,219,610			208,330			886,830
Acquisition of property, plant and equipment		(855,249	)		(4,878,770	)		(2,439,947	)		(7,506,451	)
Net cash used in investing activities		(508,365	)		(3,659,160	)		(2,231,617	)		(6,619,621	)
Exchange gain on cash and cash equivalents		510,738			347,410			768,765			930,188
Increase (decrease) in cash and cash equivalents		484,176			(5,049,274	)		805,472			(14,846,322	)
Cash and cash equivalents, beginning of period		91,562,252			94,489,647			91,240,956			104,286,695
Cash and cash equivalents, end of period		92,046,428			89,440,373			92,046,428			89,440,373
Cash paid for interest		696,361			231,563			1,295,796			477,639
Cash paid for income taxes		-			-			-			-
Supplemental schedule of non-cash activities:
Acquisition of property, plant and equipment included in
accounts payable and accrued liabilities		3,750,767			9,962,278			3,750,767			9,962,278